Klaria accelerates its business development efforts

With Klaria’s Sumatriptan Alginate Film product in approval process Klaria is now accelerating its business development efforts and has engaged Ernst & Young AB Corporate Finance (EY) to identify potential strategic partnerships for its assets. In line with this, several options are being considered that could lead to different potential outcomes, with the objective to maximize shareholder value.

Klaria will cooperate with EY to identify and establish contacts with potential strategic partners. The primary focus will be to secure a  partner for the sumatriptan product in both the EU and US – the company is expecting to receive market authorization on a number of European markets by Q3 2024. Additionally, the company will seek partnerships for the the international rights to the epinephrine film program (outside the U.S. where the rights have been licensed to Imbrium Therapeutics). Klaria will also consider partnerships or other agreements for the remaining projects including Klaria’s alginate drug delivery technology.

All potential outcomes, including licensing or divestments, that could maximize shareholder value, will be considered.

The ambition is to reach agreements during autumn 2024.